Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment,

Vertex Pharmaceuticals said the Food and Drug Administration approved a new treatment for cystic fibrosis. The treatment, called alyftrek, is designed to treat cystic fibrosis in patients six years and older who have at least one F508del mutation or another mutation that is responsive to alyftrek.